Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has been awarded a notice of allowance for its fourth patent from the US Patent and Trademark office plus a second notice of allowance for its third patent in Mexico.
These new patents strengthen the intellectual property case for the Canadian biopharma’s flagship drug candidate CaPre, an omega-3 phospholipid that treats severe hypertriglyceridemia, which occurs when triglyceride levels rise.
Indeed, the new patents broaden Acasti’s claims for its drug to include any composition containing the two long-chain omega-3 fatty acids – EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), where at least half of the composition consists of phospholipids, a key class of lipids.
In other news, Acasti is also on the receiving end of a favorable decision by the Japan Patent Office, securing its second patent for CaPre in Japan.
“The United States and Mexico represent important markets for Acasti, given the high prevalence of hypertriglyceridemia and the need for an effective, safe and well-absorbing omega-3 therapeutic for the treatment of cardiovascular-related diseases,” said Dr. Pierre Lemieux, Acasti’s chief operating officer and chief scientific officer in a statement.
“These patents strengthen the company’s strategic position in these important markets, which could support valuable commercial opportunities in the future. In addition, Acasti’s success in upholding its patent in Japan is another confirmation of the strength of our claims and IP portfolio,” he added.
Acasti CEO Jan D’Alvise expects to submit a meeting request for CaPre with the Food and Drug Administration by the close of March. “We look forward to reporting further developments, including an update on a meeting date as soon as it has been set,” D’Alvise said.
Shares added 11.5% in Toronto to C$0.58 each.
---Updates for share price---